Key clinical point: Continuation of tumor necrosis factor (TNF) inhibitor therapy throughout the vaccination period was safe and did not hamper the immune response elicited by BNT162b2 (BioNTech-Pfizer) mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis (PsA).
Major finding: There was no change in Clinical Disease Activity Index in patients with PsA before and after vaccination ( P = .92). After 2 doses of BNT162b2 mRNA SARS-CoV-2 vaccine, all patients with PsA showed a positive immune response with mean anti-SARS-CoV-2 antibody level not significantly different from matched controls ( P = .08).
Study details: Findings are from a prospective study including 40 patients with PsA on TNF inhibitor therapy matched with 40 healthy controls; both groups received 2 shots of the BNT162b2 mRNA SARS-CoV-2 vaccine.
Disclosures: The study did not report any source of funding. The authors declared no conflict of interests.
Source: Venerito V et al. RMD Open. 2022; 8:e001847 (Jan 5). Doi: 10.1136/ rmdopen-2021-001847 .